Company news
CelLBxHealth plc news in 2019
CelLBxHealth plc's news releases, calls and decks from 2019, newest first.
Cancer centre shows Parsortix use in melanoma
November 7, 2019
Q-submission to FDA containing headline data
October 30, 2019
Notice of AGM
October 8, 2019
European patent granted for megakaryocyte analysis
October 4, 2019
Use of Parsortix in head and neck cancer
September 13, 2019
Research with Parsortix in prostate cancer
September 10, 2019
Parsortix for Neuroendocrine Analysis in SCLC
September 4, 2019
Initiation of Ovarian Cancer Study
August 29, 2019
Prelim Results for the year ended 30 April 2019
July 31, 2019
Use of Parsortix for single cell analysis of CTCs
July 22, 2019
Result of General Meeting anf Total Voting Rights
July 12, 2019
Result of Placing
June 25, 2019
Parsortix used to investigate immunotherapy target
June 21, 2019
Completion of Ovarian Cancer Pre-Study
June 5, 2019
Positive Results from FDA Clinical Study
May 31, 2019
Immune suppressor cells promote metastasis
April 26, 2019
Parsortix used in new cancer assessment technique
April 18, 2019
Lung cancer study uses ANGLE's Parsortix system
April 12, 2019
AACR 2019
April 4, 2019
Enrolment complete for FDA clinical study
March 7, 2019
First subjects enrolled in ovarian cancer study
February 28, 2019
Customer demonstrates new use for Parsortix
February 25, 2019
Research into role of immune cells in cancer
February 11, 2019
New application for Parsortix in cancer analysis
January 29, 2019
Breakthrough cancer research using Parsortix
January 10, 2019